Time to spotlight folks doing great work in R&D strategy and trial design, including excellence in AI, diversity, RWE, and patient-facing technology. Nominate them for the Citeline Awards; deadline is now March 1. ow.ly/34jn50QFEfU
Denise Peterson retweeted
A holiday gift for anyone wondering what I was up to for @PharmaScrip at #ASH24 a few weeks ago: one of my long reads about what’s happening in sickle cell disease is free to read without a subscription. scrip.citeline.com/SC149532/…
Denise Peterson retweeted
Replying to @PharmaPinkSheet
@PharmaPinkSheet previously reported on sponsor's plans to contest withdrawal - get caught up here pink.pharmaintelligence.info…
Replying to @FDA
@US_FDA formally announces proposal to withdraw accelerated approval of $ONCO Pepaxto for multiple myeloma, publishes notice of opportunity for public comment under FDORA expedited withdrawal procedures public-inspection.federalreg…
My comrade Brenda Sandburg several years ago profiled pioneering photojournalist Betty Steele, who died recently. Here’s an short – and wonderful – clip of Brenda interviewing Betty. Inspiring.
youtube.com/watch?v=JK1i6WyP… This clip shows some of Betty's amazing photos.
Denise Peterson retweeted
Join host @jrovner and panelists @shefalil, @SarahKarlin, and @AliceOllstein for a new health-packed ep. of #WTHealth! This week's discussion includes reproductive health, drug pricing, legislation for organ transplants, and more! kffhealthnews.org/news/podca…
My TrialScope colleagues are benchmarking how biopharmas balance clinical trial reporting compliance/transparency with redacting sensitive company & patient data. If you’re involved in this area, help us out by taking this brief confidential survey: bit.ly/44dN5yH
Denise Peterson retweeted
More on the House Republican drug shortage bill this came from, from me last week: pink.pharmaintelligence.info…
Thomas Wicks, a Citeline colleague & trial transparency SME, is benchmarking how pharma is balancing transparency with needs to redact or anonymize some data. Help us out with our survey. #clinicaltrials #redaction #transparency
surveymonkey.com/r/CCI_LI
Denise Peterson retweeted
A handy, quick reference for tracking industry lawsuits over the IRA's drug price negotiation provisions pink.pharmaintelligence.info…
Denise Peterson retweeted
Saudi FDA’s membership to PIC/s means that it can become a reference authority for inspecting pharmaceutical factories, reports @ScripFrancesca
pink.pharmaintelligence.info…
Denise Peterson retweeted
Wow - only 6 voting members on panel, 2 of whom are regular members of the PCNSDAC. In all my many many years of covering adcomms have never seen a panel that small.
Denise Peterson retweeted
Our first day #BIO2023 notefrom from me, @ScripMandy and Kevin Grogan.
pink.pharmaintelligence.info…
Denise Peterson retweeted
(2/2) And here is @PinkSheetSutter's look at Pepaxto from the FDA perspective ... #PinkSheet #pharma: pink.pharmaintelligence.info…
Denise Peterson retweeted
(1/2) An interesting look at the saga of Pepaxto from our @ScripFrancesca and @PinkSheetSutter today. This is Francesca's look at the EMA perspective ... #pinksheet #pharma: Oncopeptides’ Melflufen: Same Data, Different Conclusions From EMA, US FDA pink.pharmaintelligence.info…
Denise Peterson retweeted
More supplemental filings from me and @SarahKarlin ... #pinksheet #pharma: Supplemental Filings: Pink Sheet Notebook On Disease Lobbying, Dan Leonard’s Next Act, And More pink.pharmaintelligence.info…
Denise Peterson retweeted
Our quick hit on the Makena situation
pink.pharmaintelligence.info…
Denise Peterson retweeted
Our take on yesterday's big neurology news from @PinkSheetSutter ... #pinksheet #pharma: @US_FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges pink.pharmaintelligence.info…
Denise Peterson retweeted
My analysis of the new OPT org chart ... #Pinksheet #Pharma: CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain pink.pharmaintelligence.info…
Denise Peterson retweeted
“We have these big societal issues and the decision about an individual product is like the tip of the spear of something that needs context,” @US_FDA's Robert Califf says about use of adcomms @SarahKarlin pink.pharmaintelligence.info…








